2017—2020年南京地区β-内酰胺类抗菌药物/β-内酰胺酶抑制剂复方制剂的使用现状调查与分析  

Investigation and Analysis on Application ofβ-Lactam Antibiotics/β-Lactamase Inhibitor Compound Preparations in Nanjing from 2017 to 2020

作　　者：胡静 罗璨 HU Jing;LUO Can(Dept.of Pharmacy,the First Affiliated Hospital of Nanjing Medical University,Nanjing 210029,China;Dept.of Healthcare,the First Affiliated Hospital of Nanjing Medical University,Nanjing 210029,China)

机构地区：[1]南京医科大学第一附属医院药学部,南京210029 [2]南京医科大学第一附属医院保健部,南京210029

出　　处：《中国医院用药评价与分析》2022年第2期242-246,251,共6页Evaluation and Analysis of Drug-use in Hospitals of China

摘　　要：目的:了解南京地区β-内酰胺类抗菌药物/β-内酰胺酶抑制剂复方制剂的使用情况,为合理用药提供依据。方法:对2017—2020年南京地区67家医院β-内酰胺类抗菌药物/β-内酰胺酶抑制剂复方制剂的销售金额、用药频度(DDDs)等数据进行统计分析。结果:2017—2020年,南京地区β-内酰胺类抗菌药物/β-内酰胺酶抑制剂复方制剂中,销售金额最高的药品为头孢哌酮舒巴坦(2∶1),DDDs排序居前2位的药品为阿莫西林克拉维酸(7∶1)、阿莫西林克拉维酸(4∶1);含舒巴坦的复方制剂的销售金额及DDDs逐年升高,同时整体占比也较高;阿维巴坦作为新的β-内酰胺酶抑制剂,2017年和2018年未在我国使用,2019年开始头孢他啶阿维巴坦的销售金额占比和DDDs占比均较小,虽然该药价格较高,但其销售金额及DDDs仍显示出明显增长趋势;临床非主流品种如头孢噻肟舒巴坦(2∶1)、头孢曲松舒巴坦(2∶1)和美洛西林舒巴坦(4∶1)等仍占据一定的使用量。结论:南京地区β-内酰胺类抗菌药物/β-内酰胺酶抑制剂复方制剂的临床使用基本能遵循相关指南要求,但是使用过程中应注意抗菌药物使用指征及选择合适配比的复方制剂,应继续加强含β-内酰胺酶抑制剂复方制剂的临床合理使用监测,促进用药合理及延缓细菌耐药性。OBJECTIVE:To investigate the application ofβ-lactam antibiotics/β-lactamase inhibitor compound preparations in Nanjing,so as to provide reference for rational drug use.METHODS:The consumption sum,daily defined dose system(DDDs)and other data ofβ-lactam antibiotics/β-lactamase inhibitor compound preparations in 67 hospitals in Nanjing from 2017 to 2020 were analyzed statistically.RESULTS:From 2017 to 2020,in terms ofβ-lactam antibiotics/β-lactamase inhibitor compound preparations in Nanjing,the drug with the highest consumption sum was cefoperazone sulbactam(2∶1),and the top 2 drugs ranked by DDDs were amoxicillin clavulanate(7∶1)and amoxicillin clavulanate(4∶1).Consumption sum and DDDs of the compound preparations containing sulbactam increased year by year,and the overall proportion was also high.Avibactam,a newβ-lactamase inhibitor,was not used in China in 2017 and 2018.Since 2019,the consumption sum proportion and DDDs proportion of ceftazidime avitabtam were both at the lower level.Although the price of the drug was higher,however,its consumption sum and DDDs still showed a significant increase trend.Clinical non-mainstream varieties such as cefotaxime sulbactam(2∶1),ceftriaxone sulbactam(2∶1)and mezlocillin sulbactam(4∶1)still occupied a certain amount.CONCLUSIONS:The clinical application ofβ-lactam antibiotics/β-lactamase inhibitor compound preparations in Nanjing basically follows the relevant guidelines,yet attention should be paid to the indications for the application of antibiotics and the selection of appropriate ratios of compound preparations during the application process,and the monitoring of rational clinical use of compound preparations containingβ-lactamase inhibitors should be strengthened to promote the rational use of drugs and delay the bacterial resistance.

关 键 词：抗菌药物 β-内酰胺类抗菌药物/β-内酰胺酶抑制剂复方制剂 用药分析 

分 类 号：R978.1[医药卫生—药品]